Updated

Citrini Research, an investment firm, attempted to prove that AI could revolutionize drug development by working with Anthropic to test whether an unreleased version of Claude could synthesize scorpion antivenom, but the experiment failed, according to The Verge. Claude generated some promising starting points but nothing approaching an actual drug, with experts noting that Citrini's team readily admitted they knew nothing about AI as applied to biology before attempting the test. The failure underscores current limitations in AI-driven pharmaceutical discovery despite industry optimism about the technology's potential.